Navigation Links
Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
Date:7/31/2008

SOUTH SAN FRANCISCO, Calif., July 31 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that the Company will present information on platinum resistance at the Fourth Annual Moores UCSD Cancer Center Translational Oncology Symposium on Friday, August 1, in San Diego.

Neela Patel, Ph.D., director of preclinical and translational medicine for Poniard Pharmaceuticals, will present on the topic of "Molecular Mechanisms of Platinum Resistance" at 2:30 p.m. Pacific Time. Jerry McMahon, Ph.D., chairman and chief executive officer, will participate in the symposia's concluding panel discussion at 3:15 p.m. Pacific Time.

"Each year, 300,000 cancer patients in the United States are treated with a platinum-based chemotherapy, and most relapse after initial treatment," said Dr. McMahon. "Therefore, intrinsic or acquired resistance to platinums is a significant treatment issue. Picoplatin, our lead product candidate, was designed to overcome platinum resistance, and we are exploring the use of genetic markers of platinum resistance to optimize patient treatment."

About The Rebecca and John Moores UCSD Cancer Center

The Rebecca and John Moores UCSD Cancer Center seeks to bring the finest minds in treatment and research under one roof to share the latest advances in the oncology field, and to create a fertile atmosphere that promotes networking and collaboration opportunities of benefit to all participants.

Information about the Moores UCSD Cancer Center and the Translational Oncology Symposium can be found at http://cancer.ucsd.edu/symposium/index.asp.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2019)... ... November 08, 2019 , ... ... in pathology research, today announced the results of analyses examining the severity ... the phase 3 selonsertib studies (STELLAR). Strong correlations were demonstrated between AI-powered ...
(Date:11/5/2019)... ... November 05, 2019 , ... Focal ... CE Mark for its Fusion Bx 2.0 prostate fusion biopsy solution. By combining ... Fusion Bx 2.0 will give urologists across Europe the ability to perform targeted ...
(Date:11/2/2019)... , ... October 31, 2019 , ... ... by pharma artificial intelligence pioneer tellic. drug360 brings tellic’s expertise in biomedical ... tool allows researchers to quickly uncover relationships between genes, diseases, variants, phenotypes, and ...
(Date:10/29/2019)... ... October 29, 2019 , ... ... to announce its Silver sponsorship and cold chain validation workshop at the Biomanufacturing ... Pines in San Diego, California. , The Biomanufacturing World Summit brings ...
Breaking Biology Technology:
(Date:11/12/2019)... ... November 12, 2019 , ... ... in the design and manufacturer of technical ergonomic seating solutions, announced this ... compliant with Healthier Hospital Initiative guidelines. Established by Practice Greenhealth, a health ...
(Date:11/12/2019)... , ... November 12, 2019 , ... ... for proposals from nonprofit U.S. universities and research institutions for its Instrumentation ... support of up to $1.2 million per site for the acquisition of instrumentation, ...
(Date:11/11/2019)... ... November 11, 2019 , ... MicroGenDX, ... played a key role in the award-winning study “Next Generation Sequencing for the ... The molecular diagnostic laboratory processed samples using Next Generation DNA Sequencing to examine ...
Breaking Biology News(10 mins):